{
  "Merck-phase3-oncology-melanoma-Pembrolizumab": {
    "title": "NCT number:  NCT02362594",
    "pharma": "Merck protocol MK-3475 -054-03",
    "study_design": "randomized, double-blind Phase 3 trial of the EORTC \nMelanoma Group\n EORTC  \nAvenue E",
    "study_treatment": "Study drugs will be administered for 1 year unless one of the",
    "study_visit": "Follow up evaluations for patients who discontinue Part 1due recurrence",
    "primary_analysis_endpoint": "\u2666 Recurrence -free survival (RFS )",
    "primary_analysis_approach": "Not specified",
    "sample_size": "450",
    "imputation_method": "mized",
    "search_phase": "Phase III",
    "search_therapeutic": "Oncology",
    "search_indication": "Melanoma",
    "detected_indication": "Melanoma",
    "source_file": "sap/Merck-phase3-oncology-melanoma-Pembrolizumab.pdf"
  }
}